ABSTRACT
RESULTS:
In the myopic group, mean preoperative endothelial cell count was 3179Ϯ531 cells/mm 2 (range: 1800 to 3900 cells/mm 2 ). The mean intraindividual endothelial cell loss was Ϫ1.83Ϯ2.25% (range: Ϫ9.09% to 0%) in the fi rst year; Ϫ1.83Ϯ2.95% (range: Ϫ7.74% to 3.80%) in the second year; and Ϫ3.20Ϯ4.43% (range: Ϫ14.25% to 1.91%) three years after surgery, compared to preoperative values. In the hyperopic group, mean preoperative endothelial cell count was 3107Ϯ125 cells/mm 2 (range: 2932 to 3300 cells/mm 2 ). The mean endothelial cell loss was Ϫ1.63Ϯ1.76% (range: Ϫ3.23% to 1.67%) in the fi rst year; Ϫ0.05Ϯ1.25% (range: Ϫ1.65% to 1.75%) in the second year; and Ϫ2.88Ϯ2.03% (range: Ϫ5.33% to Ϫ0.13%) three years after surgery, compared to preoperative values.
CONCLUSIONS: Annual cumulative cell loss was Ϫ1.9% for the myopic group and Ϫ1.6% for the hyperopic group, which is two to three times greater than physiological annual cell loss in normal eyes without surgery. An annual endothelial cell count analysis is highly recommended in every patient after iris-claw lens implantation to detect potential progressive cell loss at an early stage. [J Refract Surg. 2007 ;23: 172-177.] I ntraocular procedures with phakic lenses represent a promising alternative in the correction of myopia, hyperopia, and astigmatism. The advantages of using phakic intraocular lenses (PIOLs) include the ability to correct high refractive errors up to 20.00 diopters (D), preservation of accommodation, and reversibility of the procedure. 1 The iris-claw PIOL has been successfully implanted over several years in phakic eyes for the correction of refractive errors. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, progressive endothelial cell loss remains a major concern with anterior chamber PIOLs. 8 Because placement of the PIOL torus in the exact astigmatism axis is mandatory, 1,10-12 toric iris-fi xated PIOL enclavation can often be associated with increased surgical manipulation in the anterior chamber. Intraoperative re-enclavation maneuvers may be necessary to fi nally position the PIOL torus exactly where it is intended. Several studies with short-term follow-up have addressed endothelial cell loss after implantation of the spherical iris-fi xated PIOL. [13] [14] [15] To our knowledge, there have been no previous reports about endothelial cell loss after implantation of the toric iris-fi xated PIOL with longer follow-up. 1, 11 This prospective study was designed to evaluate 3-year follow-up changes in endothelial cell loss after implantation of the toric iris-fi xated PIOL. Eyes were divided into a myopic group (n=28) and hyperopic group (n=12). All eyes were examined before and 1, 2, and 3 years after surgery.
PATIENTS AND METHODS
Patients aged Ͼ18 years, with stable refraction for at least 1 year and astigmatism Ͼ1.50 D, with an otherwise normal ophthalmologic examination, and with unsatisfactory correction with spectacles or contact lenses for medical, professional, or personal requirements, were included in the study. All patients were fully informed about the details and possible risks of the procedure. Written informed consent was obtained from all patients before surgery in accordance with the Declaration of Helsinki. The study was approved by the local ethics committee. Exclusion criteria were anisometropia, anterior segment pathology, inadequate eyelid closure, endothelial cell count Ͻ1800 cells/mm 2 , anterior chamber depth Ͻ3.0 mm, abnormal iris or pupil function, fi xed pupil size Ͼ4.5 mm, recurrent or chronic uveitis, any form of cataract, previous corneal or intraocular surgery, intraocular pressure (IOP) Ͼ21 mmHg, glaucoma or family history of glaucoma, retinal detachment or family history of retinal detachment, pre-existing macular degeneration or macular pathology, systemic diseases, chronic treatment with corticosteroids or any immunosuppressive treatment or state, and pregnancy.
The toric Artisan lens (Ophtec BV, Groningen, The Netherlands; Verisyse, Advanced Medical Optics Inc, Santa Ana, Calif), consists of Perspex CQ-UV polymethylmethacrylate with Tinuvin 326, a benzotriazole exhibiting effective ultraviolet light fi ltration up to approximately 400 nm. The optic diameter is 5.0 mm and the overall length 8.5 mm. Available PIOL powers range from Ϫ3.00 to Ϫ23.50 D for myopia and ϩ2.00 to ϩ12.00 D for hyperopia, with a cylindrical correction from 1.00 to 7.00 D in 0.50-D increments.
PRE-AND POSTOPERATIVE VISITS
Pre-and postoperative endothelial cell counts were performed using the RhineTec Sea Eagle endothelial non-contact specular microscope (RhineTec, Krefeld, Germany). The surface of the endothelium that was scanned measured 970ϫ720 µm. Fifty images were automatically generated to analyze the center of the cornea. Automatic hexagonal cell count (with optional manual cell count) was performed, and mean values were derived. Percentage loss in endothelial cell count (ECC) was calculated using the following formula:
Preoperative preparation was the same as for typical cataract surgery but included miotic drops (pilocarpine 1% to 2%) to prepare the iris for lens fi xation. A superior sclerocorneal self-sealing 5.1-to 5.3-mm incision and two paracenteses were created in all eyes. A cohesive ophthalmic viscosurgical device (Healon OVD, Advanced Medical Optics Inc) was injected through the paracenteses to maintain a suffi cient anterior chamber depth and protect endothelial cells. The precise cylindrical axial orientation of the PIOL was determined using marks on the limbus that had been placed immediately before surgery or natural structures such as iris crypts, pigments, or vessels identifi ed via photographs. The lens was then enclavated onto the iris. If necessary, a re-enclavation maneuver was performed to ensure precise placement of the PIOL torus at the intended astigmatism axis. At the end of the implantation procedure all viscoelastic material was removed.
Endothelial cell count was evaluated 1, 2, and 3 years postoperatively. A descriptive statistical analysis was conducted using SPSS Version 11.0 (SPSS Inc, Chicago, Ill). Continuous variables were described with mean, standard deviation, median, minimum, and maximum values. Box plots were used for annual analysis of endothelial cell loss.
RESULTS
Patient age ranged from 21 to 61 years in the myopic group, and from 25 to 49 years in the hyperopic group. Twenty-three eyes were female, and 17 eyes were male. Patient demographic data are shown in Table 1 .
MYOPIC GROUP
The mean preoperative spherical equivalent refraction was Ϫ9.84Ϯ4.98 D (range: Ϫ21.50 to Ϫ2.50 D). The mean anterior chamber depth was 3.67Ϯ0.36 mm (range: 3.03 to 4.23 mm). The mean preoperative endothelial cell count was 3179Ϯ531 cells/mm 2 (range: 1800 to 3900 cells/mm 2 ). One year postoperatively, the mean change in endothelial cell count was 3276Ϯ313 cells/mm 2 , indicating an intraindividual cell change of Ϫ1.83Ϯ2.25% (range: Ϫ9.09% to 0%). Two years postoperatively, the mean endothelial cell count was 3069Ϯ523 cells/mm 2 , indicating a Ϫ1.83Ϯ2.95% mean loss (range: Ϫ7.74% to 3.80%). Three years postoperatively, the mean endothelial cell count was 2925Ϯ444 cells/mm 2 , signifying a mean loss of Ϫ3.20Ϯ4.43% (range: Ϫ14.25% to 1.91%).
HYPEROPIC GROUP
The mean preoperative spherical equivalent refraction was ϩ3.43Ϯ1.58 D (range: ϩ1.50 to ϩ6.25 D). The mean anterior chamber depth was 3.32Ϯ0.266 mm The mean cumulative endothelial cell loss per year was Ϫ1.9% in the myopic group and Ϫ1.6% in the hyperopic group. Descriptive analysis and P values are given in Table 2 . Figures 1 and 2 represent the absolute change in mean endothelial cell count per year and the relative endothelial cell count losses over time per group.
COMPLICATIONS
No intraoperative complications occurred. Postoperatively, one eye experienced transient corneal edema, which resolved completely after 1 week. Immediately after surgery, two eyes experienced increased intraocular pressure (IOP), which normalized without the need for local therapy after 1 day. A postoperative wound leak with low IOP (4 to 8 mmHg) and fl attening of the anterior chamber occurred in one eye, requiring a suture closure of the corneoscleral tunnel incision. Successful repositioning of the lens was performed in one hyperopic eye 1 week postoperatively because of deviation from the target axis.
DISCUSSION
Progressive endothelial cell loss is a major concern in anterior chamber PIOLs. Several studies 2, 15 have addressed this potential mid-and long-term complication after implantation of the iris-fi xated IOL in phakic eyes with variable outcomes. Especially for the hyperopic eye with small anterior segment anatomy, long-term evolution in terms of segment anatomical changes and long-term perspective is of high interest.
Our study represents the fi rst report of endothelial cell count changes after implantation of the toric irisfi xated PIOL in a 3-year follow-up. The mean intraindividual endothelial cell loss in the myopic group was Ϫ1.83% 1 year postoperatively, Ϫ1.83% 2 years postoperatively, and Ϫ3.20% 3 years postoperatively compared to preoperative values. In the hyperopic group, the mean intraindividual endothelial cell loss was Ϫ1.63% 1 year postoperatively, Ϫ0.05% 2 years postoperatively, and Ϫ2.88% 3 years postoperatively, compared to preoperative values.
Several studies have been published addressing this type of complication after iris-claw lens implantation; the majority of studies were performed for myopic correction.
For myopic eyes Landesz et al 2, 3 reported a progressive endothelial cell loss of Ϫ5.5% after 6 months, Ϫ7.2% after 12 months, and 9.1% after 2 years. Their 2001 study showed no signifi cant change in endothelial cell density from baseline.
2 Perez-Santonja et al 4, 13 described an endothelial cell loss of Ϫ7.3% at 3 months, Ϫ10.6% at 6 months, Ϫ13.0% at 1 year, and Ϫ17.6% at 2 years after implantation. Menezo et al 14 reported a mean endothelial loss of Ϫ3.9% at 6 months, Ϫ6.6% at 1 year, Ϫ9.2% at 2 years, Ϫ11.7% at 3 years, and Ϫ13.4% at 4 years after implantation. At 2 years after implantation, the hexagonality and coeffi cient variation in endothelial cell size were close to the preoperative levels. The morphological changes recovered, suggesting that endothelial damage occurred primarily during the surgical procedure. A correlation was detected between anterior chamber depth or implant power and amount of endothelial cell loss. The shallower the anterior chamber depth or the higher the implant power (thicker PIOL), the higher the cell loss. However, a comparison to our results is diffi cult because Menezo et al used bi-concave models, and we implanted the current, modifi ed model, which is convex-concave. In the US Food and Drug Administration clinical study of 765 eyes implanted with the Artisan PIOL, Pop and Payette 15 reported implantation of the myopic irisclaw lens did not result in signifi cant change in endothelial cell density up to 2 years after surgery. Percentage change from baseline at 6, 12, and 24 months was Ϫ0.09Ϯ16.39%, Ϫ0.78Ϯ16.35%, and 0.78Ϯ17.41%, respectively. No correlation between implant power and endothelial cell loss was observed. In a study of 60 myopic eyes, Benedetti et al 16 reported a mean endothelial cell loss of Ϫ2.8% at 4 months, Ϫ3.9% at 12 months, and Ϫ5.4% at 24 months.
In a clinical study of 57 hyperopic eyes, Alio et al 9 reported an overall corneal endothelial cell loss of Ϫ9.4% at 1-year follow-up. In a prospective study including 27 myopic eyes with a mean preoperative astigmatism of Ϫ3.43Ϯ0.81 D that underwent toric correction via toric iris-claw lens implantation, Guell et al 11 demonstrated a mean gain of endothelial cells of Ϫ2.9% 12 months postoperatively. In 16 eyes that underwent toric iris-claw lens implantation for correction of postkeratoplasty astigmatism, Nuijts et al 17 reported a mean endothelial cell loss of Ϫ7.6Ϯ18.9% at 3 months and Ϫ16.6Ϯ20.4% at last follow-up (18 months). Dick et al 1 demonstrated a 4.5% mean total loss of endothelial cell count in 70 eyes after toric irisclaw lens implantation during the fi rst 6 months after surgery.
Our data revealed lower signifi cant endothelial cell loss values compared to those described by Dick et al 1 18 found a mean cell loss of 0.6Ϯ0.5% per year over a 10-year period. Higher rates of chronic endothelial cell loss occur after anterior segment intraocular surgery such as cataract surgery (approximately 2.5% per year from 1 to 10 years after surgery) or penetrating keratoplasty (approximately 7.8% per year from 3 to 5 years after surgery).
Intraoperative endothelial cell loss could occur in hyperopic eyes, particularly those with a shallow anterior chamber. Extensive eye rubbing and PIOL dislocation due to insuffi cient iris enclavation may also cause endothelial cell loss. 8 Thus, strict patient selection, extensive surgical training, patient education (eg, instructing patients not to rub the eye excessively after surgery), and diligent follow-up are crucial factors in decreasing the risk of progressive endothelial cell loss.
The results of our study emphasize the importance of excluding eyes with a central anterior chamber depth Ͻ3.0 mm and a preoperative endothelial cell All patients in this study were strongly encouraged to return annually for an endothelial cell count analysis. Meticulous follow-up is important, especially with eyes having low baseline cell counts.
